GGrantIndex
← Leaderboards

Marc L Peters-Golden

University Of Michigan At Ann Arbor

$18,470,174
Attributed
$18,916,408
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,916,408 · 7

By mechanism

R01$9,753,169 · 3
R35$6,502,791 · 1
P50$2,277,468 · 2
R56$382,980 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungInsightSignal TransductionDinoprostoneCyclic AmpCellsMediatingFibroblastsAlveolar MacrophagesRegulationProteinsLung DiseasesPulmonary FibrosisMacrophageMolecularProstaglandinsCyclic Amp-Dependent Protein KinasesFoundationsLipid MediatorPhenotypeCell TypeResistancePropertyNovel Therapeutic Intervention

Grant awards (40)

Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$936,000
R35 · FY2025 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$917,279
R35 · FY2024 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$936,000
R35 · FY2023 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$928,378
R35 · FY2022 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$928,378
R35 · FY2021 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$928,378
R35 · FY2020 · HL · contact PI
Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis$928,378
R35 · FY2019 · HL · contact PI
Secreted SOCS Proteins as Vectors of Lung Macrophage to Epithelial Cell Crosstalk$574,738
R01 · FY2018 · HL · contact PI
Secreted SOCS Proteins as Vectors of Lung Macrophage to Epithelial Cell Crosstalk$577,781
R01 · FY2017 · HL · contact PI
Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation$388,750
R01 · FY2017 · HL · contact PI
Secreted SOCS Proteins as Vectors of Lung Macrophage to Epithelial Cell Crosstalk$565,260
R01 · FY2016 · HL · contact PI
Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation$388,750
R01 · FY2016 · HL · contact PI
Secreted SOCS Proteins as Vectors of Lung Macrophage to Epithelial Cell Crosstalk$501,268
R01 · FY2015 · HL · contact PI
Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation$381,806
R01 · FY2015 · HL · contact PI
Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation$393,484
R01 · FY2014 · HL · contact PI
Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation$370,090
R01 · FY2013 · HL · contact PI
Prostanoids, Plasminogen Actication, and Personalized Therapeutics in IPF$446,234
P50 · FY2012 · HL · contact PI
Eicosanoids and lung macrophage antimicrobial mechanisms$379,150
R01 · FY2012 · HL · contact PI
Control of fibroblast function by prostaglandin E2 and plasminogen activation$375,913
R01 · FY2012 · HL · contact PI
Prostanoids, Plasminogen Actication, and Personalized Therapeutics in IPF$446,234
P50 · FY2011 · HL · contact PI
Eicosanoids and lung macrophage antimicrobial mechanisms$382,980
R01 · FY2011 · HL · contact PI
Control of fibroblast function by prostaglandin E2 and plasminogen activation$379,710
R01 · FY2011 · HL · contact PI
Eicosanoids and lung macrophage antimicrobial mechanisms$382,980
R01 · FY2010 · HL · contact PI
Control of fibroblast function by prostaglandin E2 and plasminogen activation$379,710
R01 · FY2010 · HL · contact PI
Eicosanoids and lung macrophage antimicrobial mechanisms$382,980
R01 · FY2009 · HL · contact PI
Control of fibroblast function by prostaglandin E2 and plasminogen activation$379,710
R01 · FY2009 · HL · contact PI
Eicosanoids and lung macrophage antimicrobial mechanisms$382,980
R56 · FY2008 · HL · contact PI
Eicosanoids and Lung Macrophage Antimicrobial Mechanisms$322,040
R01 · FY2007 · HL · contact PI
Eisosanoid imbalance in fibrotic lung disease$359,880
P50 · FY2006 · HL · contact PI
Eicosanoids and Lung Macrophage Antimicrobial Mechanisms$331,658
R01 · FY2006 · HL · contact PI
Eisosanoid imbalance in fibrotic lung disease$351,932
P50 · FY2005 · HL
Eicosanoids and Lung Macrophage Antimicrobial Mechanisms$339,639
R01 · FY2005 · HL
Eicosanoids and Lung Macrophage Antimicrobial Mechanisms$339,639
R01 · FY2004 · HL
EICOSANOIDS AND LUNG MACROPHAGE ANTIMICROBIAL MECHANISMS$302,000
R01 · FY2003 · HL
EICOSANOIDS AND LUNG MACROPHAGE ANTIMICROBIAL MECHANISMS$302,000
R01 · FY2002 · HL
Eisosanoid imbalance in fibrotic lung disease$208,827
P50 · FY2002 · HL
EICOSANOIDS AND LUNG MACROPHAGE ANTIMICROBIAL MECHANISMS$302,000
R01 · FY2001 · HL
DEFICIENT CYCLOOXYGENASE EXPRESSION IN IPF FIBROBLASTS$208,827
P50 · FY2001 · HL
EICOSANOIDS AND LUNG MACROPHAGE ANTIMICROBIAL MECHANISMS$329,133
R01 · FY2000 · HL
DEFICIENT CYCLOOXYGENASE EXPRESSION IN IPF FIBROBLASTS$255,534
P50 · FY2000 · HL